Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease

Blood Cells, Molecules, and Diseases

Volumn 50, Issue 3, 2013, Pages 206-211

  van Dussen, L ^a   Zimran, A ^b   Akkerman, E M ^a   Aerts, J M F G ^a   Petakov, M ^c   Elstein, D ^b   Rosenbaum, H ^d   Aviezer, D ^e   Brill Almon, E ^e   Chertkoff, R ^e   Maas, M ^a   Hollak, C E M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d RAMBAM MEDICAL CENTER   (Israel)

^e Protalix Biotherapeutics   (Israel)

Author keywords

Bone marrow fat fraction; Gaucher disease; Quantitative chemical shift imaging; Taliglucerase alfa

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; TALIGLUCERASE ALFA;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; BONE MARROW; BONE MARROW FAT FRACTION; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; FEMALE; FIXED DRUG ERUPTION; FOLLOW UP; GAUCHER DISEASE; GAUCHER DISEASE TYPE 1; HUMAN; IMAGING; INFUSION RELATED REACTION; INFUSION SITE PAIN; LOW DRUG DOSE; LUMBAR SPINE; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUANTITATIVE CHEMICAL SHIFT IMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADIPOSE TISSUE; ADULT; AGED; ANTIBODIES; ANTIBODIES, NEUTRALIZING; BONE MARROW; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

DAUCUS CAROTA;

EID: 84873272012     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2012.11.001     Document Type: Article

References (30)

1. Zimran A., Elstein E. Lipid Storage Diseases. Williams Hematology 2010, 1065-1073. McGraw-Hill, New York. 8th edition. K. Kaushansky, M.A. Lichtman, E. Beutler, T.J. Kipps, U. Seligsohn, J.T. Prchal (Eds.).
2. Cox T.M., Schofield J.P. Gaucher's disease: clinical features and natural history. Baillieres Clin. Haematol. 1997, 10:657-689.
3. Mankin H.J., Rosenthal D.I., Xavier R. Gaucher disease. New approaches to an ancient disease. J. Bone Joint Surg. Am. 2001, 83-A:748-762.
4. de Fost M., van Noesel C.J., Aerts J.M., et al. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 2008, 93:1119-1120.
5. DeMayo R.F., Haims A.H., McRae M.C., Yang R., Mistry P.K. Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease. AJR Am. J. Roentgenol. 2008, 191:115-123.
6. Barton N.W., Brady R.O., Dambrosia J.M., et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 1991, 324:1464-1470.
7. Charrow J., Dulisse B., Grabowski G.A., Weinreb N.J. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin. Genet. 2007, 71:205-211.
8. Rosenthal D.I., Doppelt S.H., Mankin H.J., et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995, 96:629-637.
9. RosenthalI D.I., Scott J.A., Barranger J., et al. Evaluation of Gaucher disease using magnetic resonance imaging. J. Bone Joint Surg. Am. 1986, 68:802-808.
10. Maas M., Poll L.W., Terk M.R. Imaging and quantifying skeletal involvement in Gaucher disease. Br. J. Radiol. 2002, 75(Suppl. 1):A13-A24.
11. Maas M., van K.C., Stoker U., et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging-initial experience. Radiology 2003, 229:554-561.
12. de Fost M., Hollak C.E., Groener J.E., et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 2006, 108:830-835.
13. Johnson L.A., Hoppel B.E., Gerard E.L., et al. Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 1992, 182:451-455.
14. Hollak C.E., Maas M., Akkerman E., den Heeten A., Aerts H. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol. Dis. 2001, 27:1005-1012.
15. Maas M., Akkerman E.M., Venema H.W., Stoker J., den Heeten G.J. Dixon quantitative chemical shift MRI for bone marrow evaluation in the lumbar spine: a reproducibility study in healthy volunteers. J. Comput. Assist. Tomogr. 2001, 25:691-697.
16. Maas M., Hollak C.E., Akkerman E.M. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am. J. Roentgenol. 2002, 179:961-965.
17. Miller S.P., Zirzow G.C., Doppelt S.H., Brady R.O., Barton N.W. Analysis of the lipids of normal and Gaucher bone marrow. J. Lab. Clin. Med. 1996, 127:353-358.
18. Rudzki Z., Okon K., Machaczka M., et al. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease - a histological study. Eur. J. Haematol. 2003, 70:273-281.
19. Boomsma J.M., van Dussen L., Wiersma M.G., et al. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. Blood Cells Mol. Dis. 2010, 44:181-187.
20. Stowens D.W., Teitelbaum S.L., Kahn A.J., Barranger J.A. Skeletal complications of Gaucher disease. Med. (Baltimore) 1985, 64:310-322.
21. Cox T.M., Aerts J.M., Belmatoug N., et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J. Inherit. Metab. Dis. 2008, 31:319-336.
22. vom Dahl S., Poll L., Di Rocco M., et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr. Med. Res. Opin. 2006, 22:1045-1064.
23. Zimran A., Brill-Almon E., Chertkoff R., et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011, 118:5767-5773.
24. Akkerman E., Maas M.A. A region-growing algorithm to simultaneously remove dephasing influences and separate fat and water in two-point Dixon imaging [abstract]. Proc. Soc. Mag. Reson. Med. Biol. 1995, 649.
25. Akkerman E., van Dussen L., Nederveen A.J., Hollak C.E., Maas M. Stability of Dixon Fat-Water Measurements during 18 Years & along Four Different Scanners [abstract]. ISMRM Workshop Fat-Water Separation: Insights, Applications & Progress in MRI, Long Beach, CA, USA 2012.
26. Aguilera B., Ghauharali-van der Vlugt K., Helmond M.T., et al. Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J. Biol. Chem. 2003, 278:40911-40916.
27. Schoonhoven A., Rudensky B., Elstein D., et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin. Chim. Acta 2007, 381:136-139.
28. Cristy M. Active bone marrow distribution as a function of age in humans. Phys. Med. Biol. 1981, 26:389-400.
29. Ishijima H., Ishizaka H., Horikoshi H., Sakurai M. Water fraction of lumbar vertebral bone marrow estimated from chemical shift misregistration on MR imaging: normal variations with age and sex. AJR Am. J. Roentgenol. 1996, 167:355-358.
30. Rosenberg M., Kingma W., Fitzpatrick M.A., Richards S.M. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999, 93:2081-2088.